(Q54595030)

English

Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/16153694

Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/16153694

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

David S. Alberts

1

object named as

David S Alberts

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/16153694

author name string

Edward V Hannigan

2

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/16153694

Ping-Yu Liu

3

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/16153694

Caroline Jiang

4

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/16153694

Sharon Wilczynski

5

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/16153694

Larry Copeland

6

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/16153694

Maurie Markman

7

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/16153694

language of work or name

0 references

publication date

8 September 2005

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/16153694

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/16153694

100

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/16153694

1

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/16153694

133-138

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/16153694

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.117

7 January 2021

Ovarian carcinoma metastatic to the diaphragm--frequently undiagnosed at laparotomy. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.117

7 January 2021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.117

7 January 2021

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.117

7 January 2021

Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.117

7 January 2021

Second-look surgery in the management of epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.117

7 January 2021

Sensitivity of human ovarian carcinoma cells to interferon and other antitumor agents as assessed by an in vitro semi-solid agar technique.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.117

7 January 2021

Human lymphoblastoid interferon in the treatment of advanced epithelial ovarian malignancies: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.117

7 January 2021

Experience with intraperitoneal alpha-2a interferon

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.117

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.117

7 January 2021

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.117

7 January 2021

Modulation of cisplatin cytotoxicity by human recombinant interferon-gamma in human ovarian cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.117

7 January 2021

Different effects of interferons, interleukin-1beta and tumor necrosis factor-alpha in normal (OSE) and malignant human ovarian epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.117

7 January 2021

A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.117

7 January 2021

Corynebacterium parvum as an immunotherapeutic agent in an ovarian cancer model

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.117

7 January 2021

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.117

7 January 2021

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.117

7 January 2021

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.117

7 January 2021

Human leukocyte interferon therapy for advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.07.117

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.YGYNO.2005.07.117

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/16153694

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 June 2018

http://europepmc.org/abstract/MED/16153694

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54595030&oldid=2076555372"